Exact Mass: 535.3179

Exact Mass Matches: 535.3179

Found 139 metabolites which its exact mass value is equals to given mass value 535.3179, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

(4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine

(4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine

C29H45NO8 (535.3145)


(4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10S,11E)-10-hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-Hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine

3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-Hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine

C29H45NO8 (535.3145)


3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine is an acylcarnitine. More specifically, it is an 3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine 3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-Hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine

(4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-Hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine

C29H45NO8 (535.3145)


(4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine is an acylcarnitine. More specifically, it is an (4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Labiatamide A

Labiatamide A

C29H45NO8 (535.3145)


   
   

1-O-methyldelphisine

1-O-methyldelphisine

C29H45NO8 (535.3145)


   
   

Leu Phe Ser Arg

Leu Phe Ser Arg

C25H41N7O6 (535.3118)


   

Lys Phe Asn Lys

(2S)-6-amino-2-[(2S)-3-carbamoyl-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-phenylpropanamido]propanamido]hexanoic acid

C25H41N7O6 (535.3118)


   

Ala Leu Tyr Arg

Ala Leu Tyr Arg

C25H41N7O6 (535.3118)


   

Phe Ile Arg Thr

(2S,3R)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid

C25H41N7O6 (535.3118)


   

Phe Ile Thr Arg

(2S)-2-[(2S,3R)-2-[(2S,3S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylpentanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Phe Lys Lys Asn

(2S)-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]hexanamido]-3-carbamoylpropanoic acid

C25H41N7O6 (535.3118)


   

Phe Lys Asn Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]-3-carbamoylpropanamido]hexanoic acid

C25H41N7O6 (535.3118)


   

Phe Leu Arg Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid

C25H41N7O6 (535.3118)


   

Phe Leu Thr Arg

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-methylpentanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Phe Asn Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-carbamoylpropanamido]hexanamido]hexanoic acid

C25H41N7O6 (535.3118)


   

Phe Arg Ile Thr

(2S,3R)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-hydroxybutanoic acid

C25H41N7O6 (535.3118)


   

Phe Arg Leu Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-hydroxybutanoic acid

C25H41N7O6 (535.3118)


   

Phe Arg Thr Ile

(2S,3S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-3-methylpentanoic acid

C25H41N7O6 (535.3118)


   

Phe Arg Thr Leu

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-4-methylpentanoic acid

C25H41N7O6 (535.3118)


   

Phe Thr Ile Arg

(2S)-2-[(2S,3S)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Phe Thr Leu Arg

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Phe Thr Arg Ile

(2S,3S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C25H41N7O6 (535.3118)


   

Phe Thr Arg Leu

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C25H41N7O6 (535.3118)


   

Ile Phe Arg Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid

C25H41N7O6 (535.3118)


   

Ile Phe Thr Arg

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-phenylpropanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Ile Arg Phe Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C25H41N7O6 (535.3118)


   

Ile Arg Thr Phe

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Ile Thr Phe Arg

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxybutanamido]-3-phenylpropanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Ile Thr Arg Phe

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Lys Phe Lys Asn

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-phenylpropanamido]hexanamido]-3-carbamoylpropanoic acid

C25H41N7O6 (535.3118)


   

Lys Lys Phe Asn

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]-3-phenylpropanamido]-3-carbamoylpropanoic acid

C25H41N7O6 (535.3118)


   

Lys Lys Asn Phe

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2,6-diaminohexanamido]hexanamido]-3-carbamoylpropanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Lys Asn Phe Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-phenylpropanamido]hexanoic acid

C25H41N7O6 (535.3118)


   

Lys Asn Lys Phe

(2S)-2-[(2S)-6-amino-2-[(2S)-3-carbamoyl-2-[(2S)-2,6-diaminohexanamido]propanamido]hexanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Leu Phe Arg Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanoic acid

C25H41N7O6 (535.3118)


   

Leu Phe Thr Arg

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-phenylpropanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Leu Arg Phe Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C25H41N7O6 (535.3118)


   

Leu Arg Thr Phe

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Leu Thr Phe Arg

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxybutanamido]-3-phenylpropanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Leu Thr Arg Phe

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Asn Phe Lys Lys

(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-phenylpropanamido]hexanamido]hexanoic acid

C25H41N7O6 (535.3118)


   

Asn Lys Phe Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-carbamoylpropanamido]hexanamido]-3-phenylpropanamido]hexanoic acid

C25H41N7O6 (535.3118)


   

Asn Lys Lys Phe

(2S)-2-[(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-amino-3-carbamoylpropanamido]hexanamido]hexanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Arg Phe Ile Thr

(2S,3R)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methylpentanamido]-3-hydroxybutanoic acid

C25H41N7O6 (535.3118)


   

Arg Phe Leu Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-4-methylpentanamido]-3-hydroxybutanoic acid

C25H41N7O6 (535.3118)


   

Arg Phe Thr Ile

(2S,3S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-hydroxybutanamido]-3-methylpentanoic acid

C25H41N7O6 (535.3118)


   

Arg Phe Thr Leu

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-hydroxybutanamido]-4-methylpentanoic acid

C25H41N7O6 (535.3118)


   

Arg Ile Phe Thr

(2S,3R)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C25H41N7O6 (535.3118)


   

Arg Ile Thr Phe

(2S)-2-[(2S,3R)-2-[(2S,3S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-hydroxybutanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Arg Leu Phe Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C25H41N7O6 (535.3118)


   

Arg Leu Thr Phe

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-hydroxybutanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Arg Thr Phe Ile

(2S,3S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-3-phenylpropanamido]-3-methylpentanoic acid

C25H41N7O6 (535.3118)


   

Arg Thr Phe Leu

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-3-phenylpropanamido]-4-methylpentanoic acid

C25H41N7O6 (535.3118)


   

Arg Thr Ile Phe

(2S)-2-[(2S,3S)-2-[(2S,3R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-3-methylpentanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Arg Thr Leu Phe

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxybutanamido]-4-methylpentanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Arg Val Val Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H41N7O6 (535.3118)


   

Arg Val Tyr Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanoic acid

C25H41N7O6 (535.3118)


   

Arg Tyr Val Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-3-methylbutanoic acid

C25H41N7O6 (535.3118)


   

Thr Phe Ile Arg

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-phenylpropanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Thr Phe Leu Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-phenylpropanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Thr Phe Arg Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C25H41N7O6 (535.3118)


   

Thr Phe Arg Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-phenylpropanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C25H41N7O6 (535.3118)


   

Thr Ile Phe Arg

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylpentanamido]-3-phenylpropanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Thr Ile Arg Phe

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Thr Leu Phe Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-methylpentanamido]-3-phenylpropanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Thr Leu Arg Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Thr Arg Phe Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methylpentanoic acid

C25H41N7O6 (535.3118)


   

Thr Arg Phe Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-3-phenylpropanamido]-4-methylpentanoic acid

C25H41N7O6 (535.3118)


   

Thr Arg Ile Phe

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Thr Arg Leu Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-phenylpropanoic acid

C25H41N7O6 (535.3118)


   

Val Arg Val Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H41N7O6 (535.3118)


   

Val Arg Tyr Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanoic acid

C25H41N7O6 (535.3118)


   

Val Val Arg Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H41N7O6 (535.3118)


   

Val Val Tyr Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Val Tyr Arg Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C25H41N7O6 (535.3118)


   

Val Tyr Val Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

Tyr Arg Val Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-methylbutanoic acid

C25H41N7O6 (535.3118)


   

Tyr Val Arg Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C25H41N7O6 (535.3118)


   

Tyr Val Val Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-methylbutanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C25H41N7O6 (535.3118)


   

PC(16:1/2:0)

3,5,9-Trioxa-4-phosphapentacos-18-en-1-aminium, 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, [R-(Z)]-

C26H50NO8P (535.3274)


   

PC 18:1

1-(9Z-hexadecenoyl)-2-acetyl-sn-glycero-3-phosphocholine

C26H50NO8P (535.3274)


   

4-[(9-cyclopentyl-6-oxo-5-propan-2-yl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide

4-[(9-cyclopentyl-6-oxo-5-propan-2-yl-7,8-dihydropyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-N-(1-methyl-4-piperidinyl)benzamide

C29H41N7O3 (535.3271)


   

(4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine

(4Z,7Z,10S,11E)-10-Hydroperoxy-12-[(1R,4S,5S,6R)-6-[(2Z)-pent-2-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]dodeca-4,7,11-trienoylcarnitine

C29H45NO8 (535.3145)


   

3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-Hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine

3-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z,11Z)-3-Hydroperoxytetradeca-1,5,8,11-tetraen-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]propanoylcarnitine

C29H45NO8 (535.3145)


   

(4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-Hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine

(4Z)-6-[(1R,4S,5S,6R)-6-[(1E,3S,5Z,8Z)-3-Hydroperoxyundeca-1,5,8-trien-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl]hex-4-enoylcarnitine

C29H45NO8 (535.3145)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (Z)-tridec-9-enoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (Z)-tridec-9-enoate

C26H50NO8P (535.3274)


   

Lnape 5:0/N-16:1

Lnape 5:0/N-16:1

C26H50NO8P (535.3274)


   

Lnape 8:0/N-13:1

Lnape 8:0/N-13:1

C26H50NO8P (535.3274)


   

Lnape 18:1/N-3:0

Lnape 18:1/N-3:0

C26H50NO8P (535.3274)


   

Lnape 15:1/N-6:0

Lnape 15:1/N-6:0

C26H50NO8P (535.3274)


   

Lnape 19:1/N-2:0

Lnape 19:1/N-2:0

C26H50NO8P (535.3274)


   

Lnape 13:1/N-8:0

Lnape 13:1/N-8:0

C26H50NO8P (535.3274)


   

Lnape 6:0/N-15:1

Lnape 6:0/N-15:1

C26H50NO8P (535.3274)


   

Lnape 14:1/N-7:0

Lnape 14:1/N-7:0

C26H50NO8P (535.3274)


   

Lnape 2:0/N-19:1

Lnape 2:0/N-19:1

C26H50NO8P (535.3274)


   

Lnape 7:0/N-14:1

Lnape 7:0/N-14:1

C26H50NO8P (535.3274)


   

Lnape 17:1/N-4:0

Lnape 17:1/N-4:0

C26H50NO8P (535.3274)


   

Lnape 3:0/N-18:1

Lnape 3:0/N-18:1

C26H50NO8P (535.3274)


   

Lnape 4:0/N-17:1

Lnape 4:0/N-17:1

C26H50NO8P (535.3274)


   

Lnape 16:1/N-5:0

Lnape 16:1/N-5:0

C26H50NO8P (535.3274)


   

[3-acetyloxy-2-[(Z)-hexadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[3-acetyloxy-2-[(Z)-hexadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H50NO8P (535.3274)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (Z)-pentadec-9-enoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (Z)-pentadec-9-enoate

C26H50NO8P (535.3274)


   

[3-butanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[3-butanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H50NO8P (535.3274)


   

[3-pentanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[3-pentanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H50NO8P (535.3274)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-octadec-9-enoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-octadec-9-enoate

C26H50NO8P (535.3274)


   

[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-nonadec-9-enoate

[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-nonadec-9-enoate

C26H50NO8P (535.3274)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (Z)-tetradec-9-enoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (Z)-tetradec-9-enoate

C26H50NO8P (535.3274)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] (Z)-heptadec-9-enoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] (Z)-heptadec-9-enoate

C26H50NO8P (535.3274)


   

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-hexadec-9-enoate

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-hexadec-9-enoate

C26H50NO8P (535.3274)


   

[2-[(Z)-pentadec-9-enoyl]oxy-3-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

[2-[(Z)-pentadec-9-enoyl]oxy-3-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C26H50NO8P (535.3274)


   

1-[(9Z)-hexadecenoyl]-2-acetyl-sn-glycero-3-phosphocholine

1-[(9Z)-hexadecenoyl]-2-acetyl-sn-glycero-3-phosphocholine

C26H50NO8P (535.3274)


A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at positions 1 and 2 are specified as (9Z)-hexadecenoyl and acetyl respectively.

   

MePC(17:1)

MePC(6:0_11:1)

C26H50NO8P (535.3274)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   
   

PC 16:1(9Z)/2:0

PC 16:1(9Z)/2:0

C26H50NO8P (535.3274)


   
   
   

PE P-16:0/5:1;O

PE P-16:0/5:1;O

C26H50NO8P (535.3274)


   
   
   
   
   
   

LPS P-20:1 or LPS O-20:2

LPS P-20:1 or LPS O-20:2

C26H50NO8P (535.3274)


   

ST 27:3;O6;Gly

ST 27:3;O6;Gly

C29H45NO8 (535.3145)


   

ST 21:2;O3;HexNAc

ST 21:2;O3;HexNAc

C29H45NO8 (535.3145)


   

Tauroursodeoxycholate (dihydrate)

Tauroursodeoxycholate (dihydrate)

C26H49NO8S (535.3179)


Tauroursodeoxycholate (Tauroursodeoxycholic acid; TDUCA) dihydrate is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK[1][2].

   

4-(acetyloxy)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate

4-(acetyloxy)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate

C29H45NO8 (535.3145)


   

10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl acetate

10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl acetate

C29H45NO8 (535.3145)


   

(2s,6s,10s,12r,15s,18s,19s,22s,23r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl acetate

(2s,6s,10s,12r,15s,18s,19s,22s,23r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl acetate

C29H45NO8 (535.3145)


   

(1s,2s,6s,9s,11r,12r,13s,14s,15s,18s,19s,22s,23s,25r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl acetate

(1s,2s,6s,9s,11r,12r,13s,14s,15s,18s,19s,22s,23s,25r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl acetate

C29H45NO8 (535.3145)


   

(1s,2s,6s,9s,10s,11r,12r,13s,14s,15s,18s,19s,22s,23s,25r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl acetate

(1s,2s,6s,9s,10s,11r,12r,13s,14s,15s,18s,19s,22s,23s,25r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl acetate

C29H45NO8 (535.3145)


   

(1s,2r,3r,4s,5r,6s,8r,9r,10r,13s,16s,17r,18r)-4-(acetyloxy)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate

(1s,2r,3r,4s,5r,6s,8r,9r,10r,13s,16s,17r,18r)-4-(acetyloxy)-11-ethyl-6,16,18-trimethoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-8-yl acetate

C29H45NO8 (535.3145)


   

3,9-bis(acetyloxy)-6-isopropyl-3,9-dimethyl-12-(n-methylacetamido)-13-methylidene-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl acetate

3,9-bis(acetyloxy)-6-isopropyl-3,9-dimethyl-12-(n-methylacetamido)-13-methylidene-15-oxatricyclo[6.6.1.0²,⁷]pentadecan-4-yl acetate

C29H45NO8 (535.3145)